All Stories

  1. Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2014, Endocrine Society

    Juan Jose Perez Ruixo

  2. Development and Validation of an HPLC-UV Method for Sorafenib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical Practice

    Article • Therapeutic Drug Monitoring, June 2014, Wolters Kluwer Health

    Juan Jose Perez Ruixo

  3. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients

    Article • Cancer Chemotherapy and Pharmacology, March 2014, Springer Science + Business Media

    Juan Jose Perez Ruixo

  4. Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients

    Article • Journal of Pharmaceutical Sciences, January 2014, Elsevier

    Juan Jose Perez Ruixo

  5. Development and Validation of a High-Performance Liquid Chromatography Ultraviolet Method for Lapatinib Quantification in Human Plasma

    Article • Therapeutic Drug Monitoring, December 2013, Wolters Kluwer Health

    Juan Jose Perez Ruixo

  6. Similar Relationship Between the Time Course of Bone Mineral Density Improvement and Vertebral Fracture Risk Reduction With Denosumab Treatment in Postmenopausal Osteoporosis and Prostate Cancer Patients on Androgen Deprivation Therapy

    Article • The Journal of Clinical Pharmacology, November 2013, Wiley

    Juan Jose Perez Ruixo

  7. The Use of Pharmacometrics to Optimize Biosimilar Development

    Article • Journal of Pharmaceutical Sciences, November 2013, Elsevier

    Juan Jose Perez Ruixo

  8. Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

    Article • Clinical Pharmacokinetics, August 2013, Springer Science + Business Media

    Juan Jose Perez Ruixo

  9. Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin

    Article • Clinical Pharmacokinetics, July 2013, Springer Science + Business Media

    Juan Jose Perez Ruixo

  10. Romiplostim dose–response in patients with myelodysplastic syndromes

    Article • British Journal of Clinical Pharmacology, May 2013, Wiley

    Juan Jose Perez Ruixo

  11. Hematopoietic Growth Factors: Focus on Erythropoiesis-Stimulating Agents

    Article • January 2013, Springer Science + Business Media

    Juan Jose Perez Ruixo

  12. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery

    Article • Cancer Chemotherapy and Pharmacology, December 2012, Springer Science + Business Media

    Juan Jose Perez Ruixo

  13. Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim in Animals

    Article • Pharmaceutical Research, December 2012, Springer Science + Business Media

    Juan Jose Perez Ruixo

  14. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis‐stimulating agent used to treat anaemia in dialysis: a meta‐analysis

    Article • British Journal of Clinical Pharmacology, December 2012, Wiley

    Juan Jose Perez Ruixo

  15. The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics

    Article • The AAPS Journal, November 2012, American Association of Pharmaceutical Scientists (AAPS)

    Juan Jose Perez Ruixo

  16. Population Pharmacokinetic–Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)

    Article • Clinical Pharmacokinetics, October 2012, Springer Science + Business Media

    Juan Jose Perez Ruixo

  17. Romiplostim Dose Response in Patients With Immune Thrombocytopenia

    Article • The Journal of Clinical Pharmacology, October 2012, Wiley

    Juan Jose Perez Ruixo

  18. Farmacocinética poblacional de cisplatino aplicada a la personalización de su dosificación en pacientes oncológicos

    Article • Farmacia Hospitalaria, September 2012, Elsevier

    Juan Jose Perez Ruixo

  19. Farmacocinética poblacional de gemcitabina aplicada a la personalización de su dosificación en pacientes oncológicos

    Article • Farmacia Hospitalaria, July 2012, Elsevier

    Juan Jose Perez Ruixo

  20. Farmacocinética poblacional de doxorubicina aplicada a la personalización de su dosificación en pacientes oncológicos

    Article • Farmacia Hospitalaria, July 2012, Elsevier

    Juan Jose Perez Ruixo

  21. Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours

    Article • Clinical Pharmacokinetics, April 2012, Springer Science + Business Media

    Juan Jose Perez Ruixo

  22. Lifespan based indirect response models

    Article • Journal of Pharmacokinetics and Pharmacodynamics, January 2012, Springer Science + Business Media

    Juan Jose Perez Ruixo

  23. Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis

    Article • Clinical Pharmacokinetics, December 2011, Springer Science + Business Media

    Juan Jose Perez Ruixo

  24. Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report

    Article • British Journal of Clinical Pharmacology, November 2011, Wiley

    Juan Jose Perez Ruixo

  25. Immunogenicity of panitumumab in combination chemotherapy clinical trials

    Article • BMC Clinical Pharmacology, November 2011, Springer Science + Business Media

    Juan Jose Perez Ruixo

  26. Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients

    Article • Cancer Chemotherapy and Pharmacology, May 2011, Springer Science + Business Media

    Juan Jose Perez Ruixo

  27. Pharmacokinetic and Pharmacodynamic Analysis of Hyperthermic Intraperitoneal Oxaliplatin-Induced Neutropenia in Subjects with Peritoneal Carcinomatosis

    Article • The AAPS Journal, January 2011, American Association of Pharmaceutical Scientists (AAPS)

    Juan Jose Perez Ruixo

  28. Application of Pharmacokinetic–Pharmacodynamic Modeling and Simulation for Erythropoietic Stimulating Agents

    Article • November 2010, Springer Science + Business Media

    Juan Jose Perez Ruixo

  29. Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

    Article • Clinical Pharmacokinetics, November 2010, Springer Science + Business Media

    Juan Jose Perez Ruixo, Brian P Smith

  30. Pharmacodynamics-Mediated Drug Disposition (PDMDD) and Precursor Pool Lifespan Model for Single Dose of Romiplostim in Healthy Subjects

    Article • The AAPS Journal, October 2010, American Association of Pharmaceutical Scientists (AAPS)

    Juan Jose Perez Ruixo

  31. Exposure‐Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis

    Article • The Journal of Clinical Pharmacology, September 2010, Wiley

    Juan Jose Perez Ruixo

  32. Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys

    Article • The AAPS Journal, August 2010, American Association of Pharmaceutical Scientists (AAPS)

    Juan Jose Perez Ruixo

  33. Modeling the Effectiveness of Paliperidone ER and Olanzapine in Schizophrenia: Meta‐Analysis of 3 Randomized, Controlled Clinical Trials

    Article • The Journal of Clinical Pharmacology, March 2010, Wiley

    Juan Jose Perez Ruixo

  34. Pharmacokinetics and Pharmacodynamics of the Erythropoietin Mimetibody™ Construct CNTO 528 in Healthy Subjects

    Article • Clinical Pharmacokinetics, September 2009, Springer Science + Business Media

    Juan Jose Perez Ruixo

  35. Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients

    Article • Pharmaceutical Research, June 2009, Springer Science + Business Media

    Juan Jose Perez Ruixo

  36. Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG‐TPOm) After Single Intravenous Dose Administration in Healthy Subjects

    Article • The Journal of Clinical Pharmacology, March 2009, Wiley

    Juan Jose Perez Ruixo

  37. Pharmacokinetics of erythropoiesis-stimulating agents

    Article • January 2009, Springer Science + Business Media

    Juan Jose Perez Ruixo

  38. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects

    Article • Cancer Chemotherapy and Pharmacology, October 2008, Springer Science + Business Media

    Juan Jose Perez Ruixo

  39. The effect of epoetin dose on hematocrit

    Article • Kidney International, September 2008, Elsevier

    Juan Jose Perez Ruixo

  40. Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells

    Article • Journal of Pharmacokinetics and Pharmacodynamics, June 2008, Springer Science + Business Media

    Juan Jose Perez Ruixo

  41. Pharmacodynamic Analysis of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Age Distribution in Healthy Subjects

    Article • Clinical Pharmacokinetics, January 2008, Springer Science + Business Media

    Juan Jose Perez Ruixo

  42. Simulation in Clinical Drug Development

    Article • October 2007, Wiley

    Juan Jose Perez Ruixo

  43. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

    Article • Cancer Chemotherapy and Pharmacology, October 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  44. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

    Article • Breast Cancer Research and Treatment, September 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  45. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily

    Article • European Journal of Clinical Pharmacology, May 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  46. Modeling Methadone Pharmacokinetics in Rats in Presence of P-glycoprotein Inhibitor Valspodar

    Article • Pharmaceutical Research, March 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  47. Exposure‐toxicity relationships for tipifarnib in cancer patients

    Article • British Journal of Clinical Pharmacology, March 2007, Wiley

    Juan Jose Perez Ruixo

  48. An Assessment of Recombinant Human Erythropoietin Effect on Reticulocyte Production Rate and Lifespan Distribution in Healthy Subjects

    Article • Pharmaceutical Research, February 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  49. Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects

    Article • Clinical Pharmacokinetics, January 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  50. Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743,??Yondelis??) in Cancer Patients

    Article • Clinical Pharmacokinetics, January 2007, Springer Science + Business Media

    Juan Jose Perez Ruixo

  51. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients

    Article • British Journal of Clinical Pharmacology, May 2006, Wiley

    Juan Jose Perez Ruixo

  52. Modelling intestinal absorption of salbutamol sulphate in rats

    Article • International Journal of Pharmaceutics, May 2006, Elsevier

    Juan Jose Perez Ruixo

  53. Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib

    Article • Cancer Chemotherapy and Pharmacology, March 2006, Springer Science + Business Media

    Juan Jose Perez Ruixo

  54. Population Cell Life Span Models for Effects of Drugs Following Indirect Mechanisms of Action

    Article • Journal of Pharmacokinetics and Pharmacodynamics, December 2005, Springer Science + Business Media

    Juan Jose Perez Ruixo

  55. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

    Article • Cancer, April 2005, Wiley

    Juan Jose Perez Ruixo

  56. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin

    Article • European Journal of Pharmaceutical Sciences, April 2005, Elsevier

    Juan Jose Perez Ruixo

  57. Ensayos clínicos virtuales, ¿realidad o ficción?

    Article • Farmacia Hospitalaria, January 2005, Elsevier

    Juan Jose Perez Ruixo

  58. Population pharmacokinetic analysis of pegylated human erythropoietin in rats

    Article • Journal of Pharmaceutical Sciences, December 2004, Elsevier

    Juan Jose Perez Ruixo

  59. Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure

    Article • Computers in Biology and Medicine, July 2003, Elsevier

    Juan Jose Perez Ruixo

  60. Multi-dimensional Function Approximation and Regression Estimation

    Article • January 2002, Springer Science + Business Media

    Juan Jose Perez Ruixo

  61. Neural Networks Ensemble for Cyclosporine Concentration Monitoring

    Article • January 2001, Springer Science + Business Media

    Juan Jose Perez Ruixo

  62. Population pharmacokinetics of cyclosporine in kidney transplant patients

    Article • Transplantation Proceedings, September 1999, Elsevier

    Juan Jose Perez Ruixo